Lung cancer trials in Italy

In Italy 272 Also abroad 2733

272 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Not yet taking people in Italy
A trial to learn how well Dato-DXd works and how safe it is with other anticancer drugs in adults with TROP2 NMR-positive non-small cell lung cancer
Where
Ancona, Candiolo, Florence, Lucca, Orbassano, Rozzano, Verona
Age
18 years and over
People
60
Run by
AstraZeneca AB
See details and how to join2025-524836-21-00 · EU 2025-524836-21-00
Phase 3Taking people
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Where
Alessandria, Bergamo, Ferrara, Meldola, Pesaro, Roma, Rome, Siena
Age
18 years and over
People
734 worldwide
Run by
NovoCure GmbH
See details and how to joinNCT06216301
Phase 3Taking people
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Where
Bergamo, Florence, Genoa, Meldola, Milan, Misterbianco, Monza, Parma, Pavia, Rome, Trento
Age
18 years and over
People
780 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06312137 · EU 2023-508012-35-00
Phase 3Taking people
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Where
Aviano, Leghorn, Milan, Naples, Padova, Ravenna, Rome
Age
18 years and over
People
348 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00
Phase 3Taking people
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Where
Bologna, Milan, Naples, Perugia, Peschiera del Garda, Rome
Age
18 years and over
People
530 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06646276 · EU 2024-515740-23-00
Phase 3Taking people
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
Where
Bergamo, Genova, Milan, Orbassano, Pisa, Roma, Siena, Verona
Age
18 years and over
People
420 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07099898
Phase 3Taking people
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Where
Bergamo, Bolzano, Catanzaro, Florence, Meldola, Milan, Modena, Naples, Pavia, Rome, Rozzano, Statte, Udine, Verona
Age
18 years and over
People
675 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07190248 · EU 2024-514500-14-00
Phase 2Taking people
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Where
Meldola, Milan, Rome
Age
18 years and over
People
140 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07252739 · EU 2025-521939-36-00
Phase 3Taking people
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Where
Milan, Monza, Orbassano, Padova, Rozzano
Age
18 years and over
People
400 worldwide
Run by
AstraZeneca
See details and how to joinNCT07291037 · EU 2024-520101-39-00
Phase 3Taking people
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Where
Milan, Rome, Rozzano, Statte
Age
18 years and over
People
400 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07431827 · EU 2024-517337-41-00
Phase 3Taking people
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Where
Aviano, Bari, Brescia, Florence, Meldola, Orbassano, Padova, Parma, Rome, Verona
Age
18 years and over
People
670 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07472517 · EU 2025-520565-51-00
Phase 3Taking people
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Where
Meldola, Milan, Modena, Orbassano, Rome
Age
18 years and over
People
310 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07554339 · EU 2025-522038-29-00
Phase 3Taking people
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
Where
Bergamo, Brescia, Candiolo, Meldola, Milan, Pavia, Peschiera del Garda
Age
18 years and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07680790 · EU 2026-526486-21-00
Phase 1/2Taking people
A Study of DS-3939a in Participants With Solid Tumors
Where
Milan, Orbassano, Pavia, Perugia, Ravenna, Rome
Age
18 years and over
People
400 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT07739966 · EU 2026-525218-75-00
Phase 3Not yet taking people in Italy
A Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC
Where
Avellino, Aviano, Bergamo, Florence, Lucca, Milan, Naples, Pesaro, Peschiera del Garda, Rome
Age
18 years and over
People
95 worldwide
Run by
Summit Therapeutics Inc.
See details and how to join2026-526300-67-00 · EU 2026-526300-67-00
Phase 1Taking people
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Where
Candiolo, Milan, Naples, Rozzano
Age
18 years and over
People
15 worldwide
Run by
Valo Therapeutics Oy
See details and how to joinNCT05492682 · EU 2024-517580-23-00
Phase 3Taking people
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Where
Bari, Bergamo, Florence, Milan, Naples, Palermo, Peschiera del Garda, Ravenna, Rome, Siena
Age
18 years and over
People
1,000 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01
Phase 3Taking people
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Where
Catanzaro, Milan, Naples, Padova, Ravenna, Rome, Verona
Age
18 years and over
People
680 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00
Phase 1/2Taking people
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Where
Florence, Meldola, Milan, Rome
Age
18 years to 64 years
People
170 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07227597 · EU 2025-521032-11-00
Phase 3Taking people
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Where
Bergamo, Florence, Milan, Novara, Perugia, Rome
Age
18 years and over
People
876 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Where
Bergamo, Florence, Milan, Modena, Monza, Perugia, Peschiera del Garda, Rome, Turin
Age
18 years and over
People
400 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01
Phase 3Taking people
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Where
Aviano, Bergamo, Bologna, Catania, Fano, Florence, Genoa, Meldola, Milan, Monza, Orbassano, Padova, Parma, Ravenna, Rome, Rozzano, Verona
Age
18 years and over
People
356 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07566052 · EU 2025-524079-22-00
Phase 1/2Taking people
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Where
Ancona, Bari, Milan, Padova, Ravenna, Rome
Age
12 years and over
People
840 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00
Phase 3Taking people
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Where
Bari, Brescia, Candiolo, Catania, Florence, Meldola, Milan, Monza, Naples, Parma, Perugia, Pesaro, Pisa, Rome, Udine
Age
18 years to 100 years
People
750 worldwide
Run by
Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00
Phase 3Taking people
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
Where
Alexandria, Padova, Perugia, Rome, Siena, Verona
Age
18 years and over
People
290 worldwide
Run by
ETOP IBCSG Partners Foundation
See details and how to joinNCT06284317 · EU 2023-508773-82-00